162 related articles for article (PubMed ID: 37621688)
1. Economic evaluation of third-line neratinib plus capecitabine versus lapatinib plus capecitabine with HER2+ metastatic breast cancer.
Ren L; Ren N; Zheng Y; Yang Y; Xu Q
Front Oncol; 2023; 13():1221969. PubMed ID: 37621688
[TBL] [Abstract][Full Text] [Related]
2. Neratinib plus capecitabine versus lapatinib plus capecitabine as the third-line therapy for HER2-positive metastatic breast cancer in China: a cost-effectiveness analysis.
Wu Y; Dong Z; Wang J; Fang Q
BMJ Open; 2022 Nov; 12(11):e065299. PubMed ID: 36379662
[TBL] [Abstract][Full Text] [Related]
3. Cost-Effectiveness of Pyrotinib Plus Capecitabine versus Lapatinib Plus Capecitabine for the Treatment of HER2-Positive Metastatic Breast Cancer in China: A Scenario Analysis of Health Insurance Coverage.
Bao Y; Zhang Z; He X; Cai L; Wang X; Li X
Curr Oncol; 2022 Aug; 29(9):6053-6067. PubMed ID: 36135045
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness of lapatinib plus capecitabine in women with HER2+ metastatic breast cancer who have received prior therapy with trastuzumab.
Delea TE; Tappenden P; Sofrygin O; Browning D; Amonkar MM; Karnon J; Walker MD; Cameron D
Eur J Health Econ; 2012 Oct; 13(5):589-603. PubMed ID: 21701940
[TBL] [Abstract][Full Text] [Related]
5. Efficacy of Neratinib Plus Capecitabine in the Subgroup of Patients with Central Nervous System Involvement from the NALA Trial.
Hurvitz SA; Saura C; Oliveira M; Trudeau ME; Moy B; Delaloge S; Gradishar W; Kim SB; Haley B; Ryvo L; Dai MS; Milovanov V; Alarcón J; Kalmadi S; Cronemberger E; Souza C; Landeiro L; Bose R; Bebchuk J; Kabbinavar F; Bryce R; Keyvanjah K; Brufsky AM
Oncologist; 2021 Aug; 26(8):e1327-e1338. PubMed ID: 34028126
[TBL] [Abstract][Full Text] [Related]
6. Analysis of the pan-Asian subgroup of patients in the NALA Trial: a randomized phase III NALA Trial comparing neratinib+capecitabine (N+C) vs lapatinib+capecitabine (L+C) in patients with HER2+metastatic breast cancer (mBC) previously treated with two or more HER2-directed regimens.
Dai MS; Feng YH; Chen SW; Masuda N; Yau T; Chen ST; Lu YS; Yap YS; Ang PCS; Chu SC; Kwong A; Lee KS; Ow S; Kim SB; Lin J; Chung HC; Ngan R; Kok VC; Rau KM; Sangai T; Ng TY; Tseng LM; Bryce R; Bebchuk J; Chen MC; Hou MF
Breast Cancer Res Treat; 2021 Oct; 189(3):665-676. PubMed ID: 34553296
[TBL] [Abstract][Full Text] [Related]
7. Neratinib Plus Capecitabine Versus Lapatinib Plus Capecitabine in HER2-Positive Metastatic Breast Cancer Previously Treated With ≥ 2 HER2-Directed Regimens: Phase III NALA Trial.
Saura C; Oliveira M; Feng YH; Dai MS; Chen SW; Hurvitz SA; Kim SB; Moy B; Delaloge S; Gradishar W; Masuda N; Palacova M; Trudeau ME; Mattson J; Yap YS; Hou MF; De Laurentiis M; Yeh YM; Chang HT; Yau T; Wildiers H; Haley B; Fagnani D; Lu YS; Crown J; Lin J; Takahashi M; Takano T; Yamaguchi M; Fujii T; Yao B; Bebchuk J; Keyvanjah K; Bryce R; Brufsky A;
J Clin Oncol; 2020 Sep; 38(27):3138-3149. PubMed ID: 32678716
[TBL] [Abstract][Full Text] [Related]
8. A phase two randomised trial of neratinib monotherapy versus lapatinib plus capecitabine combination therapy in patients with HER2+ advanced breast cancer.
Martin M; Bonneterre J; Geyer CE; Ito Y; Ro J; Lang I; Kim SB; Germa C; Vermette J; Wang K; Wang K; Awada A
Eur J Cancer; 2013 Dec; 49(18):3763-72. PubMed ID: 23953056
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis of capecitabine plus bevacizumab versus capecitabine alone in elderly patients with previously untreated metastatic colorectal cancer from Chinese societal perspective.
Zhang PF; Wen F; Zhou J; Huang JX; Zhou KX; Wu QJ; Wang XY; Zhang MX; Liao WT; Li Q
Clin Transl Oncol; 2020 Jan; 22(1):103-110. PubMed ID: 31062173
[TBL] [Abstract][Full Text] [Related]
10. Cost-Effectiveness of Ribociclib plus Letrozole Versus Palbociclib plus Letrozole and Letrozole Monotherapy in the First-Line Treatment of Postmenopausal Women with HR+/HER2- Advanced or Metastatic Breast Cancer: A U.S. Payer Perspective.
Mistry R; May JR; Suri G; Young K; Brixner D; Oderda G; Biskupiak J; Tang D; Bhattacharyya S; Mishra D; Bhattacharyya D; Dalal AA
J Manag Care Spec Pharm; 2018 Jun; 24(6):514-523. PubMed ID: 29799329
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness Analysis of Trastuzumab Emtansine as Second-line Therapy for HER2-Positive Breast Cancer in China.
Zhang H; Zhang Y; Huang C; Wang J
Clin Drug Investig; 2021 Jun; 41(6):569-577. PubMed ID: 33876415
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of utidelone plus capecitabine for metastatic breast cancer in China.
Liao M; Jiang Q; Hu H; Han J; She L; Yao L; Ding D; Huang J
J Med Econ; 2019 Jun; 22(6):584-592. PubMed ID: 30808230
[No Abstract] [Full Text] [Related]
13. Cost-Effectiveness Analysis of Bevacizumab plus Paclitaxel versus Bevacizumab plus Capecitabine for HER2-Negative Locally Recurrent or Metastatic Breast Cancer.
Wu Q; Wang X; Zhang M; Liao W; Wang F; Li Q
Oncol Res Treat; 2020; 43(4):153-159. PubMed ID: 32187596
[TBL] [Abstract][Full Text] [Related]
14. Cost-effectiveness analysis of trastuzumab emtansine (T-DM1) in human epidermal growth factor receptor 2 (HER2): positive advanced breast cancer.
Le QA; Bae YH; Kang JH
Breast Cancer Res Treat; 2016 Oct; 159(3):565-73. PubMed ID: 27572338
[TBL] [Abstract][Full Text] [Related]
15. Cost-effectiveness of ribociclib plus endocrine therapy versus placebo plus endocrine therapy in HR-positive, HER2-negative breast cancer.
Le V; Zhong L; Narsipur N; Hays E; Tran DK; Rosario K; Wilson L
J Manag Care Spec Pharm; 2021 Mar; 27(3):327-338. PubMed ID: 33645243
[No Abstract] [Full Text] [Related]
16. Safety and efficacy of neratinib in combination with capecitabine in patients with metastatic human epidermal growth factor receptor 2-positive breast cancer.
Saura C; Garcia-Saenz JA; Xu B; Harb W; Moroose R; Pluard T; Cortés J; Kiger C; Germa C; Wang K; Martin M; Baselga J; Kim SB
J Clin Oncol; 2014 Nov; 32(32):3626-33. PubMed ID: 25287822
[TBL] [Abstract][Full Text] [Related]
17. Cost Effectiveness Analysis of Eribulin Mesylate as a Treatment for Metastatic Breast Cancer in Spain: Management in the Later Line of Therapy.
Tremblay G; Majethia U; Kontoudis I; De Rosendo J
J Health Econ Outcomes Res; 2016; 3(2):180-193. PubMed ID: 37663315
[No Abstract] [Full Text] [Related]
18. Evaluation of Tucatinib in HER2-Positive Breast Cancer Patients With Brain Metastases: A United States-Based Cost-Effectiveness Analysis.
Dong L; Lin S; Zhong L; Nian D; Li Y; Wang R; Zhou W; Weng X; Xu X
Clin Breast Cancer; 2022 Jan; 22(1):e21-e29. PubMed ID: 34238670
[TBL] [Abstract][Full Text] [Related]
19. Lapatinib for the treatment of HER2-overexpressing breast cancer.
Jones J; Takeda A; Picot J; von Keyserlingk C; Clegg A
Health Technol Assess; 2009 Oct; 13 Suppl 3():1-6. PubMed ID: 19846022
[TBL] [Abstract][Full Text] [Related]
20. Cost-Effectiveness of Second-Line Endocrine Therapies in Postmenopausal Women with Hormone Receptor-positive and Human Epidermal Growth Factor Receptor 2-negative Metastatic Breast Cancer in Japan.
Lertjanyakun V; Chaiyakunapruk N; Kunisawa S; Imanaka Y
Pharmacoeconomics; 2018 Sep; 36(9):1113-1124. PubMed ID: 29707743
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]